Print Page   |   Contact Us   |   Sign In   |   Create a Profile
News & Press: Industry News

Guided Therapeutics’ Fourth Quarter Orders of LuViva® Advanced Cervical Scan Disposables Triple 2014

Monday, October 19, 2015   (0 Comments)
Posted by: Angela King
Share |

NORCROSS, Ga.--()--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it expects to ship 25 LuViva® Advance Cervical Scan units and approximately 40,000 single-patient-use disposables in the fourth quarter of 2015.

The shipments are destined for Turkey, Saudi Arabia and Indonesia with manufacturing underway at the Guided Therapeutics facility in Norcross, Georgia.

For the year, the company expects to have shipped 45 LuViva units and approximately 45,000 disposables generating revenue of $1.1 million. This compares to 41 units and approximately 15,000 disposables in 2014 for revenue of $758,000.

“The tremendous burst of sales in the fourth quarter is reflective of closing the Turkish Ministry of Health order and shows the opportunity for growth based on our strategy of working with governments,” said Gene Cartwright, CEO of Guided Therapeutics. “Our primary targets are countries that need a point-of-care solution for cervical cancer screening of large underserved populations.”

Worldwide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit:

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in our prior financings and our ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent filings.


IRTH Communications
Robert Haag, 866-976-4784
Managing Partner
Guided Therapeutics
Bill Wells, 770-242-8723

Source. BusinessWire.

more Calendar

Bench to Business, A Commercialization Workshop Series: Session 5

Careers in Life Sciences Series: Finance, Consulting and Business

Membership Software Powered by®  ::  Legal